back to Canada directory
canada clinical guidance

Polymyalgia rheumatica (PMR)

A Canadian clinical summary of polymyalgia rheumatica (pmr), with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Alberta is used as an explicit Canadian implementation example, not as a national rule. Verify the equivalent pathway, formulary and escalation route in the patient鈥檚 province or territory.

Alberta source: bounded use

Recognition of a polymyalgia-rheumatica presentation and immediate screening for giant-cell arteritis within the Alberta GCA pathway. This is not a complete PMR treatment or taper guideline.
sources for this section:AHS GCA/PMR boundary

Source-attributed clinical priorities

  • Confirm a compatible proximal pain and stiffness syndrome while excluding mimics such as rheumatoid disease, infection, malignancy and myopathy.
  • Ask actively about cranial and ischemic symptoms of giant-cell arteritis at presentation and follow-up.
  • Route visual symptoms, jaw or tongue claudication, ischemic neurology or other GCA features through the urgent Alberta pathway; seek rheumatology input for atypical or unresolved presentations.
  • A compatible proximal stiffness syndrome should trigger assessment for mimics and active screening for giant-cell-arteritis features; response to steroid is not a stand-alone diagnosis.
sources for this section:AHS GCA/PMR boundary

Practical assessment and management workflow

1
Document bilateral shoulder or hip-girdle pain, morning stiffness, systemic symptoms and functional loss.
2
Examine joints, true muscle power, vision, pulses and temporal arteries and obtain targeted inflammatory and mimic investigations.
3
Apply the Alberta GCA pathway when cranial, visual, ischemic or large-vessel features are present.
4
Seek rheumatology review for atypical features, diagnostic uncertainty or an unresolved course rather than inferring a treatment protocol from this source.
sources for this section:AHS GCA/PMR boundary

Safety, red flags and urgent escalation

  • New visual symptoms, jaw or tongue claudication, scalp tenderness or neurologic ischemia suggests giant-cell arteritis and needs urgent action.
  • True muscle weakness, markedly abnormal muscle enzymes or another focal finding should prompt diagnostic reconsideration.
  • A complete PMR glucocorticoid dose, taper, relapse and toxicity-prevention plan requires a separate exact source.
sources for this section:AHS GCA/PMR boundary

Confirm the local pathway before acting

Alberta is used as an explicit Canadian implementation example, not as a national rule. Verify the equivalent pathway, formulary and escalation route in the patient鈥檚 province or territory.
sources for this section:AHS GCA/PMR boundary

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:AHS GCA/PMR boundary

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Alberta Health ServicesProvincial Giant Cell Arteritis Primary Care Clinical Pathway (polymyalgia-rheumatica recognition boundary)Updated 2025-05; partial-scope source checked 2026-08-20 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.